ferroptosis inducer - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	ferroptosis inducer	go back to main search page
Accession:	CHEBI:173085	browse the term
Definition:	Any substance that induces or promotes ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms.
Synonyms:	related_synonym:	ferroptosis inducers
	xref:	PMID:31899616; PMID:32015325; PMID:33167414; PMID:34012798; Wikipedia:Ferroptosis

show annotations for term's descendants Sort by:
Rat (15737) Mouse (16312) Human (16876) Chinchilla (0) Bonobo (0) Dog (4) Squirrel (0) Pig (54) Green Monkey (0) Naked Mole-rat (0) All
Genes (54)

cisplatin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family B (MDR/TAP), member 1

multiple interactions

Cisplatin inhibits the reaction [ABCB1 protein results in increased susceptibility to NSC73306]

NCBI chr 9:93,049,955...93,146,469

G

apoptosis inducing factor mitochondria associated 1

affects response to substance

AIFM1 protein affects the susceptibility to Cisplatin

NCBI chr X:106,676,596...106,708,290
Ensembl chr X:106,670,520...106,708,317

G

BCL2 associated X, apoptosis regulator

multiple interactions
affects localization

Bezafibrate inhibits the reaction [Cisplatin affects the localization of BAX protein]

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,147

G

caspase 2

increases expression

Cisplatin results in increased expression of CASP2

NCBI chr18:6,946,432...6,966,088
Ensembl chr18:6,941,937...6,966,061

G

caspase 3

increases expression
multiple interactions
increases activity

Cisplatin results in increased expression of CASP3
[Cisplatin co-treated with EPO protein] results in increased cleavage of CASP3 protein; Bezafibrate inhibits the reaction [Cisplatin results in increased cleavage of and results in increased activity of CASP3 protein]; Cilastatin inhibits the reaction [Cisplatin results in increased activity of CASP3 protein]; Cisplatin results in increased cleavage of and results in increased activity of CASP3 protein

PMID:12712633 PMID:16316343 PMID:20435919 PMID:21497595

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

caspase 8

increases activity
increases expression
multiple interactions

Cisplatin results in increased activity of CASP8 protein
Cisplatin results in increased expression of CASP8
Cilastatin inhibits the reaction [Cisplatin results in increased activity of CASP8 protein]

PMID:12712633 PMID:20435919

NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468

G

caspase 9

increases expression
increases activity

Cisplatin results in increased expression of CASP9
Cisplatin results in increased activity of CASP9 protein

PMID:12712633 PMID:20435919

NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007

G

cytochrome c, somatic

affects localization
multiple interactions

Cisplatin affects the localization of CYCS protein
Bezafibrate inhibits the reaction [Cisplatin affects the localization of CYCS protein]

NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866

G

erythropoietin

multiple interactions

[Cisplatin co-treated with EPO protein] results in increased cleavage of CASP3 protein

NCBI chr 3:8,620,508...8,622,936
Ensembl chr 3:8,620,508...8,622,936

G

Fas cell surface death receptor

increases expression

Cisplatin results in increased expression of FAS mRNA

NCBI chr14:100,927,305...100,954,781
Ensembl chr14:100,927,089...100,956,716

G

Fas ligand

multiple interactions
affects localization

Cilastatin inhibits the reaction [Cisplatin affects the localization of FASLG protein]

NCBI chr 9:115,068,314...115,075,147
Ensembl chr 9:115,068,090...115,076,464

G

glutamate-cysteine ligase catalytic subunit

multiple interactions

Buthionine Sulfoximine inhibits the reaction [sulforaphane inhibits the reaction [Cisplatin results in decreased activity of GCLC protein]]; sulforaphane inhibits the reaction [Cisplatin results in decreased activity of GCLC protein]

NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,565...27,253,530

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [Cisplatin results in increased expression of MYC]

NCBI chr 4:12,455,141...12,460,360
Ensembl chr 4:12,455,122...12,461,078

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

Dicumarol inhibits the reaction [sulforaphane inhibits the reaction [Cisplatin results in decreased activity of NQO1 protein]]; sulforaphane inhibits the reaction [Cisplatin results in decreased activity of NQO1 protein]

NCBI chr 6:17,292,962...17,302,593
Ensembl chr 6:17,292,770...17,302,590

G

poly(ADP-ribose) polymerase 1

increases activity
multiple interactions

Cisplatin results in increased activity of PARP1 protein
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Cisplatin results in increased activity of PARP1 protein]

NCBI chr10:14,203,157...14,241,164
Ensembl chr10:14,203,160...14,241,196

G

peroxisome proliferator activated receptor alpha

decreases activity
multiple interactions

Cisplatin results in decreased activity of PPARA protein
[Cisplatin results in decreased activity of PPARA protein] which results in increased abundance of Fatty Acids, Nonesterified; Bezafibrate inhibits the reaction [[Cisplatin results in decreased activity of PPARA protein] which results in increased abundance of Fatty Acids, Nonesterified]; Bezafibrate inhibits the reaction [Cisplatin results in decreased activity of PPARA protein]

NCBI chr 5:3,302,755...3,321,091
Ensembl chr 5:3,300,741...3,364,239

G

tumor necrosis factor

increases expression

Cisplatin results in increased expression of TNF mRNA

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,415

G

tumor protein p53

increases expression
multiple interactions

Cisplatin results in increased expression of TP53
mangostin inhibits the reaction [Cisplatin results in increased expression of TP53]

PMID:12712633 PMID:20603111

NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818

disulfiram

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450 family 2 subfamily E member 1

multiple interactions

Disulfiram inhibits the reaction [4-xylene results in increased activity of CYP2E1 protein]; Disulfiram inhibits the reaction [Toluene results in increased activity of CYP2E1 protein]

NCBI chr14:141,690,737...141,703,078
Ensembl chr14:141,690,426...141,736,817

G

tumor necrosis factor

multiple interactions

Disulfiram inhibits the reaction [TNF protein results in increased abundance of Reactive Oxygen Species]

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,415

folic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catalase

multiple interactions

[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] promotes the reaction [bisphenol A results in decreased expression of CAT protein]; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT mRNA; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT protein

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

cystathionine beta-synthase

multiple interactions
increases activity

[Ethanol co-treated with Folic Acid deficiency] results in increased activity of CBS protein
Folic Acid deficiency results in increased activity of CBS protein

NCBI chr13:206,205,942...206,231,363
Ensembl chr13:206,205,946...206,230,248

G

colony stimulating factor 2

multiple interactions

[Folic Acid co-treated with Glycine] results in decreased expression of CSF2 mRNA

NCBI chr 2:134,354,724...134,357,155
Ensembl chr 2:134,354,724...134,357,155

G

cystathionine gamma-lyase

multiple interactions

[Ethanol co-treated with Folic Acid deficiency] results in increased activity of CTH protein

NCBI chr 6:142,454,922...142,486,352
Ensembl chr 6:142,454,914...142,486,367

G

DNA methyltransferase 1

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT1 mRNA

NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844

G

DNA methyltransferase 3 alpha

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of DNMT3A mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT3A mRNA

NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,603,087

G

glutamate-cysteine ligase catalytic subunit

multiple interactions

[Ethanol co-treated with Folic Acid deficiency] results in increased activity of GCLC protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GCLC mRNA

NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,565...27,253,530

G

glutathione peroxidase 1

multiple interactions

[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of GPX1 mRNA; [bisphenol A co-treated with [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12]] results in increased expression of GPX1 mRNA

NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433

G

glutathione-disulfide reductase

multiple interactions
increases activity
increases expression

[Ethanol co-treated with Folic Acid deficiency] results in increased activity of GSR protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSR mRNA
Folic Acid deficiency results in increased activity of GSR protein
Folic Acid deficiency results in increased expression of GSR mRNA

NCBI chr15:54,382,564...54,433,989
Ensembl chr15:54,382,567...54,433,984

G

glutathione synthetase

multiple interactions

[Ethanol co-treated with Folic Acid deficiency] results in increased activity of GSS protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSS mRNA

NCBI chr17:38,316,199...38,342,253
Ensembl chr17:38,312,720...38,342,298

G

glutathione S-transferase alpha 1

increases expression
multiple interactions

Folic Acid deficiency results in increased expression of GSTA1 mRNA
[Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSTA1 mRNA

NCBI chr 7:46,538,743...46,550,781
Ensembl chr 7:46,538,032...46,548,670

G

glycogen synthase 1

multiple interactions

[Betaine co-treated with Choline co-treated with Folic Acid co-treated with bisphenol A] results in increased methylation of GYS1 promoter; [Betaine co-treated with Choline co-treated with Folic Acid] results in decreased expression of GYS1 mRNA; [Betaine co-treated with Choline co-treated with Folic Acid] results in increased methylation of GYS1 promoter

NCBI chr 6:54,234,600...54,250,211
Ensembl chr 6:54,233,050...54,250,261

G

lactate dehydrogenase A

multiple interactions

[bisphenol A co-treated with Choline co-treated with Folic Acid co-treated with Betaine] results in decreased methylation of LDHA promoter

NCBI chr 2:40,814,163...40,827,284
Ensembl chr 2:40,814,169...40,826,715

G

methylenetetrahydrofolate reductase

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of MTHFR mRNA

NCBI chr 6:71,863,637...71,882,118
Ensembl chr 6:71,863,637...71,881,820

G

prostaglandin-endoperoxide synthase 1

multiple interactions

[Folic Acid co-treated with Glycine] results in decreased expression of PTGS1

NCBI chr 1:262,456,106...262,482,159
Ensembl chr 1:262,456,155...262,483,035

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[Folic Acid co-treated with Glycine] results in increased expression of PTGS2

NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884

G

sucrase-isomaltase

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SI mRNA

NCBI chr13:104,296,281...104,379,558
Ensembl chr13:104,296,283...104,379,478

G

solute carrier family 15 member 1

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of SLC15A1 mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased methylation of SLC15A1 promoter]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC15A1 mRNA

NCBI chr11:67,652,808...67,690,457
Ensembl chr11:67,652,193...67,710,933

G

solute carrier family 5 member 1

multiple interactions

[Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with bisphenol A] results in increased expression of SLC5A1 mRNA; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC5A1 mRNA

NCBI chr14:48,566,400...48,704,145
Ensembl chr14:48,628,224...48,705,841

G

superoxide dismutase 1

decreases activity
multiple interactions

Folic Acid deficiency results in decreased activity of SOD1 protein
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of SOD1 mRNA; [Ethanol co-treated with Folic Acid deficiency] results in decreased activity of SOD1 protein

PMID:16792574 PMID:29129240

NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729

G

superoxide dismutase 2

multiple interactions
increases activity

[Ethanol co-treated with Folic Acid deficiency] results in increased activity of SOD2 protein
Folic Acid deficiency results in increased activity of SOD2 protein; Folic Acid results in increased activity of SOD2 protein

PMID:16792574 PMID:22889112

NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560

N(5)-ethyl-L-glutamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX mRNA]

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,147

G

BCL2 apoptosis regulator

multiple interactions

theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 mRNA]

NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879

G

caspase 3

multiple interactions

theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP3 mRNA]

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

claudin 1

multiple interactions

[N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of CLDN1 mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of CLDN1 protein]; theanine inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]

PMID:37271275 PMID:38438008

NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657

G

interleukin 6

multiple interactions

theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of IL6 mRNA]

NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263

G

lactate dehydrogenase A

multiple interactions

theanine inhibits the reaction [Hydrogen Peroxide results in increased activity of LDHA protein]

NCBI chr 2:40,814,163...40,827,284
Ensembl chr 2:40,814,169...40,826,715

G

interleukin-1 beta-like

multiple interactions

[N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of IL1B mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]

PMID:37271275 PMID:38438008

G

mitogen-activated protein kinase 14

multiple interactions

[SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK14 mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of MAPK14 protein]; theanine inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK14 mRNA]

PMID:37271275 PMID:38438008

NCBI chr 7:31,791,398...31,861,544
Ensembl chr 7:31,790,877...31,862,031

G

NLR family pyrin domain containing 3

multiple interactions

[N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]

NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228

G

occludin

multiple interactions

[N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of OCLN mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of OCLN protein]; theanine inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]

PMID:37271275 PMID:38438008

NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

theanine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of RELA protein]

NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469

G

tight junction protein 1

multiple interactions

theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of TJP1 mRNA]; theanine inhibits the reaction [Hydrogen Peroxide results in decreased expression of TJP1 protein]

NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836

G

tumor necrosis factor

multiple interactions

theanine inhibits the reaction [Hydrogen Peroxide results in increased expression of TNF mRNA]

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,415

paracetamol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cyclin dependent kinase inhibitor 1A

decreases expression

Acetaminophen results in decreased expression of CDKN1A protein

NCBI chr 7:32,354,776...32,363,771
Ensembl chr 7:32,354,672...32,363,761

G

tumor protein p53

decreases expression

Acetaminophen results in decreased expression of TP53 protein

NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818

S-butyl-DL-homocysteine (S,R)-sulfoximine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutamate-cysteine ligase catalytic subunit

multiple interactions
decreases activity

Buthionine Sulfoximine inhibits the reaction [sulforaphane inhibits the reaction [Cisplatin results in decreased activity of GCLC protein]]
Buthionine Sulfoximine results in decreased activity of GCLC protein

NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,565...27,253,530

simvastatin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions
decreases expression

Simvastatin promotes the reaction [Ezetimibe results in increased expression of HMGCR mRNA]
Simvastatin results in decreased expression of HMGCR mRNA

PMID:17130282 PMID:19343539

NCBI chr 2:84,380,245...84,401,117
Ensembl chr 2:84,380,224...84,402,957

G

low density lipoprotein receptor

multiple interactions
increases expression

Simvastatin promotes the reaction [Ezetimibe results in increased expression of LDLR mRNA]
Simvastatin results in increased expression of LDLR mRNA

NCBI chr 2:69,828,348...69,864,823
Ensembl chr 2:69,828,332...69,864,827

G

NPC1 like intracellular cholesterol transporter 1

multiple interactions

Simvastatin promotes the reaction [Ezetimibe results in increased expression of NPC1L1 mRNA]

NCBI chr18:50,726,854...50,757,676
Ensembl chr18:50,726,922...50,757,649

G

nuclear receptor subfamily 4 group A member 3

decreases expression

Simvastatin results in decreased expression of NR4A3 mRNA

NCBI chr 1:241,569,867...241,611,735
Ensembl chr 1:241,570,010...241,611,727

G

sterol regulatory element binding transcription factor 1

multiple interactions

[Ezetimibe co-treated with Simvastatin] results in increased expression of SREBF1 mRNA

NCBI chr12:60,733,967...60,750,951
Ensembl chr12:60,733,907...60,751,267

G

sterol regulatory element binding transcription factor 2

multiple interactions

Simvastatin promotes the reaction [Ezetimibe results in increased expression of SREBF2 mRNA]

NCBI chr 5:6,719,484...6,784,724
Ensembl chr 5:6,719,490...6,784,671

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	5151
role	5118
biological role	5118
biochemical role	5042
ferroptosis inducer	54
BAY11-7085	0
CM-272	0
DPI2	0
FIN56	0
FINO2	0
JQ1	0
L-buthionine-(S,R)-sulfoximine +	1
L-glutamic acid +	32
ML-210	0
ML162	0
RSL3	0
RSL5	0
S-butyl-DL-homocysteine (S,R)-sulfoximine	1
artesunate	0
cisplatin	18
disulfiram	2
erastin	0
ferric ammonium citrate	0
ferroptocide	0
ferrous ammonium sulfate (anhydrous) +	0
hemin	0
iFSP1	0
lanperisone	0
lanperisone hydrochloride	0
paracetamol +	2
simvastatin	6
sorafenib +	0
sulfasalazine	0
talaroconvolutin A	0
thiostrepton	0

paths to the root